FDAnews Device Daily Bulletin
July 23, 2012 | Vol. 9 No. 143
Makers of hip, knee and shoulder joint implants have two years from July 1, 2012, to apply for their products to be transitioned from Class IIb to Class III devices in Australia, the Therapeutic Goods Administration (TGA) said.
After 12 years, the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA) has officially incorporated in the U.S., a move that will allow it to better influence discussions on global medical imaging concerns, an association official says.
Medical devices often use commercial PCs and have wireless connections that make them vulnerable to malware, or require software updates for security, but the U.S. may not be doing an adequate job tracking these risks, researchers indicated in a study published Friday.
A new study has found that the biomedical device industry must change the way it does business in order to compete in today’s competitive global market.
Second Sight Medical Products announced that an FDA Ophthalmic Devices Advisory Panel has been scheduled to review the data presented in the company’s HDE market approval application for its Argus II Retinal Prosthesis System.
The pain of interstitial cystitis can be as unrelenting as the urge to urinate.
Lazarus Effect, a medical device company focused on improving treatment of acute ischemic stroke through effective removal of the blood clots that cause a stroke, announced today that the Lazarus Funnel Guide Catheter has received CE Mark.
Baxter International said its net income rose 7 percent in the second quarter on one-time gains and better sales of a hemophilia drug, blood plasma products and dialysis devices.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.